- ASSISTANT PROFESSOR Genetics and Genomic Sciences
PhD, University of Western Ontario
Dr. Argmann has a doctorate from the faculty of Science at the University of Western Ontario, Canada where she showed that PPARγ and LXR activation could dramatically reduce macrophage foam cell formation, a key event in atherosclerosis. During her postdoctoral studies at the Institut de Génétique et de Biologie Moléculaire et Cellulaire in Strasbourg, France she contributed to the development of high-throughput mouse metabolic phenotyping protocols and demonstrated that resveratrol, a compound found in red wine, improves mitochondrial function and protects against metabolic disease in vivo.
She then started as a research scientist in Dr Schadt’s genetics group at Rosetta Inpharmatics where she contributed to the designing of large-scale genetic mouse crosses to address novel facets of metabolic disease. She was involved in integrating DNA variation, gene expression, and clinical data collected, in order to uncover core networks associated with metabolic disease processes, which in turn were used to identify novel therapeutic targets for the Diabetes and Obesity franchise.
In 2010, during her postdoctoral position in Dr. Aerts’s lab at the Academic Medical Center of the University of Amsterdam, she developed her current line of research which she continues now as an assistant professor at Mount Sinai in the Institute for Genomics and Multiscale Biology. Her work involves extending the genetics of gene expression strategy to include intermediate phenotypes, such as sphingolipidomics data, to address the role of these lipids in metabolic disease-related pathophysiologies. In addition, she is using these ‘complex disease’ strategies to identify candidate modifier genes of inborn errors of metabolism, such as Gaucher’s disease severity. The ultimate goal is to develop a general network medicine approach for inborn errors of metabolism.
For a complete list of Dr. Argmann's publications click here
Selected research interests
1. Network medicine for inborn errors of metabolism: Despite their seemingly monogenetic nature, many inborn errors of metabolism, such as Gaucher’s disease, have a remarkably heterogeneous clinical presentation making the disease course and severity difficult to predict. In fact, from a contemporary perspective there is no clear distinction between simple Mendelian disorders and complex diseases such that collectively these disorders represent a continuum of diminishing effects from a single gene influenced by modifier genes to increasingly shared influence by multiple genes. This realization highlights the need for an unbiased approach to finding candidate modifier genes for seemingly ‘monogenetic’ diseases and reveals the possibility of applying an experimental model system ‘designed’ for complex diseases to inborn errors of metabolism. Our preliminary research is demonstrating that experimental model systems successfully utilized to advance our understanding of complex disease (e.g. genetics of gene expression data in complex genetic reference populations of mice) are equally useful in advancing our understanding of inborn errors of metabolism, in particular by revealing the molecular networks underlying Gaucher’s disease severity.
2. Network medicine for Complex metabolic diseases: Genetics of gene expression strategies have been very successful in bringing novel insight into complex disease pathophysiology. However, metabolites are more likely to serve as the most proximal reporters of a phenotype and yield critical biological insights. Since individual metabolyte profiles or metabotypes in analogy with genotype, have been shown to be determined by genetics and environment, we propose to extend the genetics of gene expression strategy to include intermediate phenotypes obtained using lipidomic and metabolomic platforms. Through statistical integration of these multi-scale layers we aim to obtain a detailed picture pathophysiology in complex disease.
Aim of the biological data mining group
Helping people extract novel biological insights from very complex and large data sets requires spanning both the biological and computational worlds. Our biological data mining group aims to do this by helping to ask the right computational questions in order to get the right biological answers. To accomplish this we entertain many collaborations and are imbedded in the Icahn Institute for Multi-scale Biology.
Houten SM, Denis S, Argmann CA, Jia Y, Ferdinandusse S, Reddy JK, Wanders RJ. Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids. Journal of lipid research 2012 Jul; 53(7).
Houtkooper RH, Argmann C, Houten SM, Cantó C, Jeninga EH, Andreux PA, Thomas C, Doenlen R, Schoonjans K, Auwerx J. The metabolic footprint of aging in mice. Scientific reports 2011; 1.
Argmann C, Dobrin R, Heikkinen S, Auburtin A, Pouilly L, Cock TA, Koutnikova H, Zhu J, Schadt EE, Auwerx J. Ppargamma2 is a key driver of longevity in the mouse. PLoS genetics 2009 Dec; 5(12).
Dobrin R, Zhu J, Molony C, Argman C, Parrish ML, Carlson S, Allan MF, Pomp D, Schadt EE. Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease. Genome biology 2009; 10(5).
Tu Z, Argmann C, Wong KK, Mitnaul LJ, Edwards S, Sach IC, Zhu J, Schadt EE. Integrating siRNA and protein-protein interaction data to identify an expanded insulin signaling network. Genome research 2009 Jun; 19(6).
Heikkinen S, Argmann C, Feige JN, Koutnikova H, Champy MF, Dali-Youcef N, Schadt EE, Laakso M, Auwerx J. The Pro12Ala PPARgamma2 variant determines metabolism at the gene-environment interface. Cell metabolism 2009 Jan; 9(1).
Argmann* C, Labouge* M, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006 Dec; 127(6).
Argmann C, Auwerx J. Insulin secretion: SIRT4 gets in on the act. Cell 2006 Sep; 126(5).
Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. The Journal of biological chemistry 2005 Jun; 280(23).
Rowe AH, Argmann CA, Edwards JY, Sawyez CG, Morand OH, Hegele RA, Huff MW. Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation. Circulation research 2003 Oct; 93(8).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Argmann is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 3 Room 3-70H
1425 Madison Avenue
New York, NY 10029